Financial, market and economic news

Emapalumab’s efficacy confirmed by sensitivity analysis presented at ESID2020

STOCKHOLM, Sweden, Oct. 17, 2020 /PRNewswire/ — Sobi™ today presented results from the sensitivity analysis from the pivotal phase 2/3 study (NCT01818492) of emapalumab in patients with primary HLH at the 19th meeting of the European Society of Immunodeficiencies (ESID). Analyses of the…

Read More

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy